A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

• ClinicalTrials.gov Identifier: NCT05544929
• Recruitment Status: Recruiting
• First Posted: September 19, 2022
• Last Update Posted: May 14, 2024
• Sponsor: Novartis Pharmaceuticals
• Information provided by (Responsible Party): Novartis ( Novartis Pharmaceuticals )

Study Description

Brief Summary:

The purpose of this study is to characterize the safety and tolerability of KFA115 and KFA115 in combination with pembrolizumab in patients with select advanced cancers, and to identify the maximum tolerated dose and/or recommended dose.

Condition or disease	Intervention/treatment	Phase
Carcinoma, Non-Small-Cell Lung; Cutaneous Melanoma; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Nasopharyngeal Carcinoma; Carcinoma, Thymic; Anal Cancer; Mesothelioma; Esophagogastric Cancer; High Microsatellite Instability Colorectal Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms	Drug: KFA115; Drug: pembrolizumab	Phase 1

Detailed Description:

This is a phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab. The study consists of a dose escalation part, followed by dose expansion part(s) for single-agent KFA115 and KFA115 in combination with pembrolizumab. The escalation parts will characterize safety and tolerability. After the determination of the maximum tolerated dose (MTD) / recommended dose (RD), the dose expansion parts will assess the preliminary anti-tumor activity in defined patient populations and further assess the safety and tolerability at MTD/RD.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 180 participants
• Allocation: Non-Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
• Actual Study Start Date: October 26, 2022
• Estimated Primary Completion Date: February 20, 2026
• Estimated Study Completion Date: February 20, 2026

Arms and Interventions

Arm	Intervention/treatment
Experimental: Single-agent KFA115; KFA115 monotherapy	Drug: KFA115; Immunomodulatory agent; Other Name: NVP-KFA115
Experimental: KFA115 run-in (1 cycle) + pembrolizumab; 1-cycle KFA115 run-in followed by addition of pembrolizumab	Drug: KFA115; Immunomodulatory agent; Other Name: NVP-KFA115; Drug: pembrolizumab; Anti-PD-1 antibody; Other Name: Keytruda
Experimental: KFA115 + pembrolizumab; KFA115 + pembrolizumab combination given concurrently	Drug: KFA115; Immunomodulatory agent; Other Name: NVP-KFA115; Drug: pembrolizumab; Anti-PD-1 antibody; Other Name: Keytruda

Outcome Measures

Primary Outcome Measures :

1. Incidence and severity of dose limiting toxicities (DLTs) during the DLT evaluation period of single-agent KFA115 (dose escalation only) [ Time Frame: 28 days ]
   A DLT is defined as an adverse event or abnormal laboratory value that occurs during the DLT evaluation period where the relationship to study treatment cannot be ruled out, and is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications and meets the criteria defined in the study protocol
2. Incidence and severity of dose limiting toxicities (DLTs) during the DLT evaluation period of KFA115 in combination with pembrolizumab (dose escalation only) [ Time Frame: 28 days ]
   A DLT is defined as an adverse event or abnormal laboratory value that occurs during the DLT evaluation period where the relationship to study treatment cannot be ruled out, and is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications and meets the criteria defined in the study protocol
3. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 35 months ]
   Incidence and severity of adverse events and serious adverse events, including changes in laboratory values, vital signs, and electrocardiograms qualifying and reported as AEs
4. Frequency of dose interruptions, reductions [ Time Frame: 35 months ]
   Number of dose interruptions of KFA115 and pembrolizumab, and number of dose reductions of KFA115
5. Dose intensity [ Time Frame: 35 months ]
   Dose intensity of KFA115 and pembrolizumab is defined as the ratio of actual cumulative dose received and actual duration of exposure

Secondary Outcome Measures :

1. Best overall response (BOR) per RECIST v1.1 [ Time Frame: 35 months ]
   BOR is defined as the best response recorded from the start of the treatment until disease progression/recurrence
2. Progression free survival (PFS) per RECIST v1.1 [ Time Frame: 35 months ]
   PFS is defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to any cause
3. Duration of response (DOR) per RECIST v1.1 [ Time Frame: 35 months ]
   DOR is defined as the time from the date of the first documented response (CR or PR) to the date of the first documented progression as per RECIST v1.1 or death due to underlying cancer
4. Time to progression (TTP) per RECIST v1.1 [ Time Frame: 35 months ]
   TTP is defined as the time from date of start of treatment to the date of event defined as the first documented progression or death due to underlying cancer
5. Area under the concentration time curve (AUC) of KFA115 or pembrolizumab [ Time Frame: During the first 168 days of treatment for single-agent KFA115 and 35 months for KFA115 in combination with pembrolizumab ]
   Area under the concentration time curve
6. Peak plasma or serum concentration (Cmax) of KFA115 or pembrolizumab [ Time Frame: During the first 168 days of treatment for single-agent KFA115 and 35 months for KFA115 in combination with pembrolizumab ]
   The maximum (peak) observed plasma or serum drug concentration after single dose administration
7. Minimum plasma or serum concentration (Cmin) of KFA115 or pembrolizumab [ Time Frame: During the first 168 days of treatment for single-agent KFA115 and 35 months for KFA115 in combination with pembrolizumab ]
   The minimum observed plasma or serum drug concentration reached during the time interval between two dose administrations
8. Time to reach peak plasma or serum concentration (Tmax) of KFA115 or pembrolizumab [ Time Frame: During the first 168 days of treatment for single-agent KFA115 and 35 months for KFA115 in combination with pembrolizumab ]
   The time to reach maximum (peak) plasma or serum drug concentration after single dose administration
9. Elimination half-life (T1/2) of KFA115 or pembrolizumab [ Time Frame: During the first 168 days of treatment for single-agent KFA115 and 35 months for KFA115 in combination with pembrolizumab ]
   The elimination half-life associated with the terminal slope of a semi logarithmic concentration-time curve

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Non-small cell lung cancer with historic PD-L1 ≥ 1%, as determined locally using a clinically accepted assay. Patients must have experienced benefit from previous anti-PD(L)1-containing therapy for at least 4 months based on investigator-assessed disease stability or response prior to developing documented disease progression. Patients must have also received prior platinum-based chemotherapy, either in combination or in sequence with anti-PD-(L)1, unless patient was ineligible to receive such treatment.
• Renal cell carcinoma, clear cell histology, previously treated with anti-PD(L)1-containing therapy and a VEGF targeted therapy as monotherapy or in combination. Patients should have documented disease progression following anti-PD(L)1-containing therapy.
• Cutaneous melanoma, previously treated with anti-PD(L)1-containing therapy. Patients should have documented disease progression following anti-PD(L)1-containing therapy. Patients with BRAF V600-mutant melanoma must have also received prior therapy with a BRAF V600 inhibitor, with or without a MEK inhibitor.
• Ovarian cancer, high-grade serous histology, naïve to anti-PD(L)1 therapy, must have received one prior systemic therapy in platinum-resistant setting.
• Nasopharyngeal carcinoma, non-keratinizing locally advanced recurrent or metastatic. Depending on the study arm, patients may be naïve to anti-PD(L)1 therapy, or previously treated with platinum-based chemotherapy with or without anti-PD-(L)1.
• Locally advanced unresectable or metastatic triple negative breast cancer, ovarian cancer (high-grade serous histology), anal cancer (squamous), MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC.
• Locally advanced unresectable or metastatic anal cancer (squamous), thymic carcinoma, MSI-H CRC, esophagogastric cancer, mesothelioma, and HNSCC, all naïve to anti-PD(L)1 therapy and for whom anti PD(L)1 therapy is not available.
• Triple negative breast cancer with historic PD-L1 CPS ≥ 1%, must have received at least one line of chemotherapy.

Exclusion Criteria:

• Impaired cardiac function or clinically significant cardiac disease.
• Use of agents known to prolong the QT interval unless they can be permanently discontinued for the duration of study.
• History of severe hypersensitivity reactions to any ingredient of study drug(s) and other mAbs and/or their excipients.
• Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur may be considered. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
• Any evidence of interstitial lung disease (ILD) or pneumonitis, or a prior history of ILD or non-infectious pneumonitis requiring high-dose glucocorticoids.
• Patients who discontinued prior anti-PD-(L)1 therapy due to an anti-PD-(L)1-related toxicity (applicable to the KFA115 in combination with pembrolizumab treatment arms).
• Patients with symptomatic peripheral neuropathy limiting instrumental activities of daily living.

Other protocol-defined inclusion/exclusion criteria may apply

Contacts and Locations

Contacts

Contact: Novartis Pharmaceuticals; 1-888-669-6682; novartis.email@novartis.com

Contact: Novartis Pharmaceuticals; +41613241111

Locations

United States, Massachusetts

Massachusetts General Hospital .; Recruiting

Boston, Massachusetts, United States, 02114

Contact: Justin Gainor 617-724-4000 jgainor@partners.org

Principal Investigator: Justin Gainor

United States, New York

NYU School of Medicine Langone Health; Recruiting

New York, New York, United States, 10015

Contact: Amy Ciriaco 212-731-5662 amy.ciriaco@nyulangone.org

Principal Investigator: Kristen Spencer

United States, Pennsylvania

University of Pittsburgh MC; Recruiting

Pittsburgh, Pennsylvania, United States, 15232

Contact: Aric Fellers 412-623-4897 fellersaj@upmc.edu

Principal Investigator: Jason Luke

United States, Tennessee

SCRI Oncology Partners Sarah Cannon new location; Recruiting

Nashville, Tennessee, United States, 37203

Contact: Katie Robbins Katerina.Robbins@scri.com

Principal Investigator: Melissa Johnson

Canada, Ontario

Novartis Investigative Site; Recruiting

Toronto, Ontario, Canada, M5G 2M9

Germany

Novartis Investigative Site; Recruiting

Dresden, Germany, 01307

Novartis Investigative Site; Recruiting

Essen, Germany, 45147

Hong Kong

Novartis Investigative Site; Recruiting

Shatin New Territories, Hong Kong

Italy

Novartis Investigative Site; Recruiting

Milano, MI, Italy, 20133

Japan

Novartis Investigative Site; Recruiting

Chuo ku, Tokyo, Japan, 104 0045

Singapore

Novartis Investigative Site; Recruiting

Singapore, Singapore, 119228

Spain

Novartis Investigative Site; Recruiting

Barcelona, Catalunya, Spain, 08035

Taiwan

Novartis Investigative Site; Recruiting

Taipei, Taiwan, 10002

Sponsors and Collaborators

Novartis Pharmaceuticals

Investigators

• Study Director: Novartis Pharmaceuticals; Novartis Pharmaceuticals

More Information

• Responsible Party: Novartis Pharmaceuticals
• ClinicalTrials.gov Identifier: NCT05544929
• Other Study ID Numbers: CKFA115A12101; 2022-502381-25 ( Registry Identifier: EU CTIS )
• First Posted: September 19, 2022
• Last Update Posted: May 14, 2024
• Last Verified: May 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):

Lung cancer; Non-small-cell lung cancer; NSCLC; Malignant Skin Cancer; Skin Cancer; Cutaneous melanoma; Renal cell carcinoma; RCC; Kidney cancer; Renal cancer; Clear cell carcinoma; Cancer of the ovaries; Female reproductive cancer; Ovarian carcinoma; Epithelial ovarian cancer; Nasopharyngeal Neoplasms; Nasopharyngeal carcinoma; NPC; Thymic carcinoma; Thymic tumor; Rectal cancer; Rectal neoplasms; Esophageal cancer; Cancer of throat; Colon cancer; Colorectal cancer; Bowel cancer; Cancer of the colon and rectum; High microsatellite instability colorectal carcinoma; CRC

Additional relevant MeSH terms:

Carcinoma; Neoplasms; Melanoma; Carcinoma, Squamous Cell; Nasopharyngeal Carcinoma; Mesothelioma; Mesothelioma, Malignant; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma, Cutaneous Malignant; Colorectal Neoplasms; Anus Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Ovarian Epithelial; Thymoma; Microsatellite Instability; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Neoplasms, Squamous Cell; Nasopharyngeal Neoplasms